Minodiab (Glipizide)

Glipizide is used to manage hyperglycaemia in type 2 diabetes mellitus, a chronic disorder of glucose metabolism.

• Type 2 diabetes mellitus: Improves glycaemic control when combined with diet and exercise, helping achieve target blood glucose levels.
• Adjunct therapy with other oral antidiabetics: Provides additional glucose‑lowering effect in patients not adequately controlled on monotherapy.
• Combination with insulin: Allows dose reduction of insulin by enhancing endogenous insulin secretion.
• Monotherapy in newly diagnosed patients: Initiates effective glucose control as first‑line oral agent.

• Glipizide binds to the sulfonylurea receptor subunit of the ATP‑sensitive potassium channel on pancreatic beta cells. This binding closes the channel, causing membrane depolarisation and opening of voltage‑dependent calcium channels. The resulting calcium influx triggers exocytosis of insulin granules, increasing circulating insulin and reducing plasma glucose concentrations. The effect is dose‑dependent and reversible, and it does not directly affect insulin sensitivity.

Glipizide may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Hypoglycaemia: Low blood sugar episodes, especially if meals are missed or dosing is excessive.
• Weight gain: Increase in body weight due to enhanced insulin activity.
• Nausea: Mild gastrointestinal discomfort or upset.
• Dizziness: Transient light‑headedness or vertigo.

Serious or Rare Side Effects

• Severe hypoglycaemia: Prolonged low glucose requiring medical intervention.
• Allergic skin reactions: Rash, pruritus or urticaria indicating hypersensitivity.
• Hematologic abnormalities: Neutropenia or agranulocytosis.
• Hepatic dysfunction: Elevated liver enzymes or hepatitis.

When prescribing Glipizide, clinicians should consider several safety measures to minimise risk.

• Monitor blood glucose: Adjust dose based on glycaemic response and avoid overt hypoglycaemia.
• Assess renal function: Use with caution in patients with impaired kidney function.
• Evaluate hepatic status: Reduce dose or avoid in significant liver disease.
• Check for sulfonylurea allergy: Discontinue if hypersensitivity signs appear.
• Store at ambient temperature below 25°C: Keep in the original pack, protect from moisture.

Glipizide can interact with other medicines, altering its glucose‑lowering effect or increasing adverse event risk.

Major Interactions (Avoid)

• Concurrent use with other sulfonylureas: Additive risk of severe hypoglycaemia.
• Combination with insulin: May cause profound hypoglycaemia.
• Co‑administration with meglitinides: Increases hypoglycaemic potential.

Moderate Interactions (Monitor Closely)

• Beta‑blockers: May mask symptoms of hypoglycaemia.
• Thiazide diuretics: Can diminish Glipizide’s glucose‑lowering efficacy.
• Corticosteroids: May raise blood glucose, reducing therapeutic effect.